Revisiting steroids in the primary treatment of acute kawasaki disease

Journal of Pediatrics

Volumn 149, Issue 3, 2006, Pages 291-292

  Burns, Jane C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; DIPYRIDAMOLE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; STEROID;

ADD ON THERAPY; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; DRUG INFUSION; DRUG MONITORING; DRUG TREATMENT FAILURE; EDITORIAL; GENOTYPE PHENOTYPE CORRELATION; HOSPITALIZATION; HUMAN; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK BENEFIT ANALYSIS; THERAPY EFFECT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; METHYLPREDNISOLONE; MUCOCUTANEOUS LYMPH NODE SYNDROME;

EID: 33747885466     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2006.07.016     Document Type: Editorial

References (11)

1. Shulman S.T. Is there a role for corticosteroids in Kawasaki disease?. J Pediatr 142 (2003) 601-603
2. Kawasaki T. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. Arerugi 16 (1967) 178-222 Shike H, Burns JC, Shimizu C. English translation of Dr. Tomisaku Kawasaki's original report of fifty patients in 1967 (Japanese). Pediatr Inf Dis J. 2002;21:993. Article plus additional online files.
3. Inoue Y., Okada Y., Tomomasa T., Takeuchi K., and Morikawa A. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease. clinical course and coronary artery outcome. J Pediatr 149 (2006) 336-341
4. Newburger J.W., Takahashi M., Beiser A.S., Burns J.C., Bastian J., Chung K.J., et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324 (1991) 1633-1639
5. Klassen T.P., Rowe P.C., and Gafni A. Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome. J Pediatr 122 (1993) 538-542
6. de Zorzi A., Colan S.D., Gauvreau K., Baker A.L., Sundel R.P., and Newburger J.W. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 133 (1998) 254-258
7. Burns J.C., Shimizu C., Gonzalez E., Kulkarni H., Patel S., Shike H., et al. Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. J Infect Dis 192 (2005) 344-349
8. Minami T., Suzuki H., Takeuchi T., Uemura S., Sugatani J., and Yoshikawa N. A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease. J Pediatr 147 (2005) 78-83
9. Newburger J.W., Takahashi M., Burns J.C., Beiser A.S., Chung K.J., Duffy C.E., et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315 (1986) 341-347
10. Kobayashi T., Inoue Y., Takeuchi K., Okada Y., Tamura K., Tomomasa T., et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 113 (2006) 2606-2612
11. Muta H., Ishii M., Furui J., Nakamura Y., and Matsuishi T. Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease. Acta Paediatr 95 (2006) 189-193